Your Health and Fitness Partner: Androxal & FitHub

We are also excited to expand our scope by including valuable information on Androxal, a potent medication beneficial in various medical conditions. This remarkable drug, derived from the testosterone molecule, has made its mark significantly in the field of endocrinology. Patients and medical professionals can rely on our comprehensive, unbiased, and scientifically grounded content on Androxal for gaining a robust understanding of its uses, side effects, and the latest studies related to it. We understand the necessity of accurate information when it comes to medication. Our newly launched section dedicated to Androxal aims at not only educating the readers about its nuances but also at contributing beneficially to their wellbeing. Stay tuned for insightful articles unraveling the potential of Androxal in medical science.

Sitemap | Policies | Feedback    
 About the Journal
Editorial Board
Journal Subscription
Instructions for Authors
E-mail Alerts
Forthcoming Events
Advertise with Us
Contact Us
 
Article Options
FULL TEXT
ABSTRACT
PDF
Printer Friendly Version
Search Pubmed for
Search Google Scholar for
Article Statistics
Bookmark and Share
 
Non-alcoholic fatty liver disease among visitors to a hepatitis awareness programme
 
Zaigham Abbas,1 Arzoo Saeed,1 Syed Mujahid Hassan,1 Nasir Hassan Luck,1 Arsalan Khan,2 Mirza Naqi Zafar,3 Kehkashan Zehra Hossain, Syed Muhammad Faiq
Departments of Hepatogastroenterology, 1 Hepatobiliary
Surgery,2 Pathology,3 Nutrition4
and Radiology,5 Sindh Institute of Urology and Transplantation,
Karachi, Pakistan


Corresponding Author
: Dr Zaigham Abbas
Email: drzabbas@gmail.com


Abstract

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The present study aimed to evaluate the prevalence of NAFLD among the visitors screened on World Hepatitis Day 2010 and 2011.

Methods: Attendees of the hepatitis awareness programme (n=928) were offered screening to rule out liver ailments. The participants were evaluated on history, body mass index (BMI) measurement, blood tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), alanine aminotransferase (ALT) levels and abdominal ultrasound (US).

Results: On ultrasonography, fatty liver was present in 142 of 806 subjects who were found negative for viral serology and had no history of regular alcohol intake. This accounted for 15.3% of all the visitors. Comparing them with the rest of the serology-negative alcoholnegative subjects, there were more housewives (p=0.005) with fatty liver. They were older with mean age 43.3+12.1 years compared to33.1+16.1 years (p=0.000) in patients without fatty liver and had a higher BMI 28.6+6.0 kg/m2 vs. 22.2+5.3 kg/m2 (p=0.000). Regression analysis suggested BMI as the only significant independent risk factor (p=0.000). However, 32 subjects with fatty liver had BMI <25 kg/m2 and 6 of them had diabetes mellitus. Thirty-one subjects (21.8%) with fatty liver had raised ALT level (p=0.000) and possible non-alcoholic steatohepatitis (NASH) which accounts for 3.34% (31/928) of the total visitors.

Conclusions: This analysis reveals that our general population is at risk of having NAFLD and NASH and these should be looked into even in non-obese persons.